EP 1620564 A4 20080312 - METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS
Title (en)
METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS
Title (de)
VERFAHREN ZUR BEHANDLUNG VON AUF APOPTOSEINDUKTION REAGIERENDEN KRANKHEITEN UND SCREENING-TESTS
Title (fr)
PROCEDES POUR TRAITER DES MALADIES ENTRAINANT L'INDUCTION D'APOPTOSE ET ESSAIS DE CRIBLAGE
Publication
Application
Priority
- US 2004011915 W 20040419
- US 46364903 P 20030418
- US 46366203 P 20030418
- US 48474903 P 20030707
- US 48475003 P 20030707
- US 53266503 P 20031229
Abstract (en)
[origin: WO2004094647A2] The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to one or more Apoptosis Inducing Proteins (AIPs). AIPs include Transferrin Receptor Related Apoptosis Inducing Proteins (TRRAIPs), Clathrin Heavy Chain Related Apoptosis Inducing Proteins (CHCRAIPs), IQ motif containing GTPase Activating Protein Related Apoptosis Inducing Proteins (IQGAPRAIPs), and Heat Shock Protein Related Apoptosis Inducing Proteins (HSPRAIPs). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using AIPs as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.
IPC 8 full level
A61K 31/352 (2006.01); A61K 38/17 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C07D 493/20 (2006.01); C07D 519/00 (2006.01)
IPC 8 main group level
C12Q (2006.01)
CPC (source: EP US)
A61K 31/352 (2013.01 - EP US); A61K 49/0043 (2013.01 - EP US); A61K 49/0052 (2013.01 - EP US); A61K 51/0412 (2013.01 - EP US); A61K 51/0419 (2013.01 - EP US); A61K 51/0421 (2013.01 - EP US); A61K 51/0453 (2013.01 - EP US); A61K 51/0495 (2013.01 - EP US); A61P 35/00 (2017.12 - EP)
Citation (search report)
- [X] CA 2396005 A1 20000803 - CYTOVIA INC [US]
- [X] US 6462041 B1 20021008 - CAI SUI XIONG [US], et al
- [X] WO 0134591 A2 20010517 - CYTOVIA INC [US]
- [X] WO 02097043 A2 20021205 - UNIV PENNSYLVANIA [US], et al
- [X] WO 02092083 A1 20021121 - CYTOVIA INC [US], et al
- See references of WO 2004094647A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL HR LT LV MK
DOCDB simple family (publication)
WO 2004094647 A2 20041104; WO 2004094647 A3 20060817; CA 2522700 A1 20041104; EP 1620564 A2 20060201; EP 1620564 A4 20080312; US 2005004026 A1 20050106; US 7592143 B2 20090922
DOCDB simple family (application)
US 2004011915 W 20040419; CA 2522700 A 20040419; EP 04750268 A 20040419; US 82690904 A 200404